Review Article The Other Side of Helicobacter Pylori Infection-Protein-Losing Gastropathy by Murata Ikuo
Acta Med. Nagasaki 47:1- 7
Review Article 
The Other Side of Helicobacter Pylori Infection-Protein-Losing Gastropathy
Ikuo MURATA
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, Nagasaki University Graduate School of Biomedical Sciences
 Helicobacter pylori (H. pylori) is now regarded as a 
pathogen for various disease of the gastrointestinal tract. 
Recent reports indicated that it rarely causes protein loss 
from the stomach leading to hypoproteinemia, a condition 
termed as protein-losing gastropathy (PLG). Several condi-
tions are recognized in protein-losing gastropathy caused 
by H. pylori. Hypertrophic gastropathy with protein-loss, 
traditionally called Menetrier's disease, is one of manifesta-
tions of this condition. This condition may be subdivided in 
two categories; hypertrophic gastropathy with minimal in-
flammation and hypertrophic gastritis with giant folds. The 
latter includes a histological entity termed hypertrophic 
lymphocytic gastritis. Varioliform gastritis that has charac-
teristic endoscopic features is another entity of the condi-
tion showing PLG, which also often shows histological fea-
tures of lymphocytic gastritis. To our knowledge, 
lymphocytic gastritis is a rarely seen in Japanese patients. 
Previously, these conditions were treated with various 
drugs such as a somatostatin analogue, H2 receptor an-
tagonist, and proton pump inhibitor, resulting in incom-
plete responses. Recently, a significant number of reports 
have documented usefulness of eradication therapy for H. 
pylori. As more than 90 % of patients with gastropathy or 
gastritis accompanying PLG are positive for H. pylori, 
treatment of its infection in these patients with PLG is rec-
ommended. 
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Introduction
 Helicobacter pylori (H. pylori) is a common bacterium 
infecting about half the world's population (1). 
Prevalence of H. pylori varies by geographical location, 
ethnic background, socioeconomic conditions, and age. 
In Japan, the prevalence of the infection exceeds 50 
of aged population. This gram-negative microorganism 
colonizes the human epithelial layer in the stomach 
and induces a state of chronic inflammation that does 
not resolve the underlying infection and often leads to 
gastric or duodenal ulcers, or more rarely to gastric 
neoplasms including carcinoma and lymphoma (2, 3) 
(Fig. 1). Infection with H. pylori has been established as 
a risk factor for gastric adenocarcinoma in the middle 
of 1990s'(4). At present, the concept of sequential pro-
gression of the gastric lesions from chronic gastritis, 
atrophic gastritis with intestinal metaplasia to forma-
tion of carcinoma in H. pylori infection is widely ac-
cepted. This sequence has been also shown in an ani-
mal model with long-term H. pylori infection (5). H. 
pylori strains with the cag pathogenicity island (PAI) 
induce particularly intense inflammatory responses of 
the gastric epithelium (6,7). This inflammation is a hy-
pothesized mechanism by which H. pylori infection 
leads to atrophic gastritis and gastric carcinoma (8, 9). 
  A recent Japanese large population study showed
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Figure 1. Progression of the gastric lesions in Helicobacter 
pylori infection.
that atrophic gastritis and intestinal metaplasia were 
strongly associated with H. pylori and not with aging 
(10). In their repot, atrophic gastritis was shown to in-
crease from 9.4% in those less than 20 years of age to 
> 70% in those aged 60 or older and to be strongly as-
sociated with H. pylori infection. The overall preva-
lence of atrophic gastritis in H. pylori infection was 
82.9% compared with 9.8% among uninfected. Intestinal 
metaplasia was present in 43.1% of H. pylori positive 
persons compared with 6.2% among the uninfected. 
The data indicates that atrophic gastritis in H. pylori 
positive Japanese was very high in the younger gen-
eration as well as in the aged one. 
 Surprisingly, most people infected with H. pylori are 
asymptomatic, which suggests that additional factors 
are necessary for the development of H. pylori-
associated diseases. These factors may affect the out-
come of H. pylori infection, including the host re-
sponse and the extent and severity of gastric 
inflammation. For example, the amount of parietal 
cells may influence acid secretion in H. pylori infec-
tion. Furthermore, gastric cancer can be caused not 
only by H. pylori infection, but also by a combination 
of various factors such as food and the environment. 
Gastric cancer is epidemiologically linked with diets 
high in salt and low in fresh fruit. Salt, a diet lacking 
antioxidant vitamins, and cigarette smoking strongly 
predispose to both peptic ulcer and gastric cancer. 
 Gastroduodenal ulcers and gastric cancer are com-
mon and serious diseases but occur in only a minority 
of people with this infection. On the other hand, H. py-
lori infection is known to cause various diseases in 
the alimentary tract and extraintestinal organs. 
Greater awareness of the spectrum of diseases other 
than peptic ulcer and carcinoma associated with H. py-
lori may well lead to their increased recognition of 
these diseases. In the stomach, lymphproliferative dis-
orders, Menetrier's disease, and hyperplastic polyps are 
reported as rare complications of H. pylori infection. 
The association has been proposed based on 
epidemiology or outcome of medical intervention such 
as H. pylori eradication. This article will briefly sum-
marize our current understanding of H. pylori-related 
protein loss from the stomach.
H. pylori-associated protein-losing gastropathy
 Protein-losing gastroenteropathy (PLE) is a rare con-
dition characterized by gastrointestinal protein loss 
leading to hyporoteinemia. Several mechanisms have 
been proposed for the plasma protein loss across the 
gastrointestinal mucosa. The plasma protein loss may
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occur through (1) inflamed or ulcerated mucosa as oc-
casionally seen in inflammatory bowel diseases, (2) 
disordered mucosal cell structures as seen in celiac 
disease, (3) the intercellular space of the mucosal epi-
thelium in the presence of increased lymphatic or ve-
nous pressures as seen in inflammatory or neoplastic 
involvement of lymphatic system, and (4) rupture of 
dilated lymphatic vessels in the mucosa as seen in in-
testinal lymphangiectasia. 
 Plasma protein loss through the gastric mucosa is 
termed as protein-losing gastropathy (PLG), which oc-
curs in combination with several conditions such as 
inflammation, neoplasia and polyposis of the stomach. 
Recently, several conditions with PLG have been 
shown to be associated with infective factors such as 
H. pylori and cytomegalovirus (11,12). PLG behaves 
somewhat differently from the general group of PLE, 
marked by excellent responses to elimination of H. py-
lori, antisecretory therapy, and surgical resection. 
There are several conditions of PLG caused by H. py-
lori. Based on our experiences and literature, 
endoscopic features of H. pylori-associated PLG can be 
roughly divided in following two categories;
1) Menetrier's disease (hypertrophic gastropathy) 
2) Erosive gastritis or varioliform gastritis
1) Menetrier's disease (hypertrophic gastropathy)
 Menetrier's disease is a well-known but rare condi-
tion that was first reported by Menetrier in 1888 (13). 
It is characterized by remarkable hypertrophy of the 
gastric mucosa accompanied by hypoproteinemia due 
to protein loss from the gastric mucosa (Fig. 2, 3). 
Associated features include hypochlorhydria, normal 
or slightly elevated fasting serum gastrin, and in-
creased risk for gastric carcinoma. Recently, it has 
been reported to be associated with H. pylori infection, 
and there are reports describing the improvement of 
Menetrier's disease after eradication therapy for H. py-
lori infection (14-19). 
 There has been controversy in recognition of 
Menetrier's disease. First described by Menetrier (13), 
the disease is a poorly delineated syndrome character-
ized by gastric rugal hypertrophy. Because it is an ill-
defined condition, the diagnosis is mainly based on 
the basis of clinical and histological criteria (13, 20, 
21). The most accepted criteria include giant folds es-
pecially in the fundus and body, hypoalbuminemia 
due to PLG, and histological features of foveolar 
hyperplasia, gland atrophy, and marked increase in 
mucosal thickness (22). However, Wolfsen et al. (23) 
indicated that there are two distinct entities in
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Figure 2. Hypertrophic gastric folds in a patient with 
Menetrier's disease.
Figure 3. Endoscopic view of the corpus showing prominent 
folds in Menetrier's disease.
conditions showing features of Menetrier's disease. 
They analyzed and reviewed 23 patients previously 
diagnosed with Menetrier's disease and found that the 
patients actually represent at least two diseases: 
Hypertrophic lymphocytic gastritis (HLG) in 13 pa-
tients and Massive foveolar hyperplasia and minimal 
inflammation (MFH) in 10 patients. Clinical features 
and frequency of H. pylori were similar in these two 
groups. Patients with HLG, which is a recently de-
scribed histological entity characterized by increased 
lymphocytes in the superficial gastric epithelium and 
foveolae (24), had severe inflammation with numerous 
intraepithelial lymphocytes and mild foveolar 
hyperplasia. Alternatively, patients with MFH had 
greater foveolar hyperplasia, significantly thicker 
mucosa, and greater mucosal edema, and less inflam-
matory cell infiltration. Therefore, they concluded that 
patients with MFH represent a form of hypertrophic 
gastropathy and should be designated as having 
Menetrier's disease, whereas patients with HLG should 
be considered part of the spectrum of lymphocytic 
gastritis. Groisman et al. (15) also reported that there 
are two distinct histopathological features regarded as 
separate entities in patients with giant gastric folds 
accompanying by a protein-losing state; hypertrophic 
lymphocytic gastritis (HLG) and classical Menetrier's 
disease. Most recent reports, however, have used the 
term "Menetrier's disease " without discussing this dis-
tinction, probably because the original description of 
this disease (13) was ill defined. I support the concept 
that there are two separate entities, namely gastritis 
and gastropathy, in conditions showing hypertrophy 
of the gastric mucosa accompanied by PLG. 
 The differential diagnosis of (classical) Menetrier's 
disease includes other forms of hypertrophic 
gastropathy such as Zollinger-Ellison syndrome, 
hypertrophic hypersecretory gastropathy, lymphocytic 
gastritis, or an infiltrating neoplasm. Very high serum 
gastrin levels should raise the possibility of Zollinger-
Ellison syndrome, which may also produce gastric 
mucosal hypertrophy with foveolar hyperplasia. 
Lymphocytic gastritis includes a subgroup of patients 
with giant gastric folds or varioliform gastritis and a 
protein-losing state, a condition termed HLG and its 
diagnosis depends on histology of biopsy specimen 
(24). 
 The frequencies of clinical manifestations in 
Menetrier's disease are follows; epigastric pain (65%), 
asthenia (60%), anorexia (45%), weight loss (45%), edema 
(37.5%), vomiting (37.5%), hypoalbuminemia of < 35 g/l 
(81%), and an abnormal enteric protein loss (85%) (18). 
We experienced several patients with Menetrier's dis-
ease, most of whom had gastrointestinal symptoms.
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Exceptionally, one case with no symptoms was found 
by general health check-up. This patient seemed to be 
healthy, except for showing hypertrophic gastropathy 
and hypoproteinemia.
2) Erosive gastritis and varioliform gastritis
  Erosive gastritis is a common disease that is caused 
by many etiologic factors such as drugs and H. pylori 
. Varioliform gastritis has a distinct gross appearance 
that is multiple aphthous erosions with surrounded by 
a ring elevation of the mucosa (25-29), and is easily 
recognized by endoscopy and barium meal study. 
Several reports have shown the close relationship be-
tween varioliform gastritis and a histological entity of 
lymphocytic gastritis (30-32). Rarely, H. pylori-related 
erosive gastritis and varioliform gastritis can be asso-
ciated with PLG when the lesions are severe enough 
to cause significant protein loss. We recently experi-
enced two rare cases with erosive gastritis leading to 
PLG and hypoproteinemia caused by H. pylori infec-
tion. One showed typical endoscopic features of 
varioliform gastritis in the body and antrum of the 
stomach (Fug. 4) (29), and another showed varioliform 
gastritis in the body and diffuse erosions in the 
antrum(Fig, 5) (33). The former patient had no signifi-
cant gastrointestinal symptoms, while the latter com-
plained severe epigastralgia and anorexia leading to 
weight loss. Endoscopy showed multiple erosions with 
abundant mucous or exudates secretion from gastric 
mucosa, and colonization of the gastric mucosa with 
H. pylori was confirmed in both cases. Histology of bi-
opsies from both patients revealed intraepithelial lym-
Figure 5. Endoscopic view of the antrum with extensive ero-
sive gastritis with protein-losing gastropathy. This patient 
had multiple erosions resembling varioliform gastritis in the 
corpus.
phocyte infiltration, but their histological findings did 
not fulfill the criteria for lymphocytic gastritis pro-
posed by Haot et al. (24) that more than 30 % of 
epithelial cells are infiltrated with intraepithelial lym-
phocytes. I consider that the incidence of lymphocytic 
gastritis fulfilling this histological criterion may be ex-
tremely low in Japan. This discrepancy between Japan 
and Western countries in the recognition of this dis-
ease needs to be elucidated in the future.
Mechanism of protein loss from the stomach
Figure 4. Endoscopic view of varioliform gastritis showing 
multiple aphthous erosions (arrows) in the antrum.
 The mechanism of gastric protein loss is 
multifactorial and includes loss through abnormal 
mucosa and superficial ulceration, a paracellular route 
via an abnormality of tight junctions, and a 
transcellular route (34, 35). Careful endoscopic obser-
vation may disclose abundant mucus secretion from 
erosions and ulcers of the stomach. Mucosal electron 
microscopy (EM) changes of vacuolization and tight 
junction abnormalities have recently been described in 
H. pylori-associated gastritis (36, 37). Badov et al. (38) 
also reported that EM of biopsies from the stomach 
showed degenerate epithelial cells with simplification 
of the tight junctions and separation of the adjacent 
cells, with markedly abnormal granular vesicles abun-
dant in the cytoplasm, and suggested that these latter 
changes were abnormally dilated Golgi apparatus and 
rough endoplasmic reticulum. Thus, the EM
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observation suggests that protein loss occurs via inter-
cellular junction disruption and altered mucus proper-
ties, as well as surface ulceration.
Diagnosis of protein loss from the stomach
 The diagnosis of PLE should be considered in all 
patients with hypoproteinemia and edema without 
other known causes. Several techniques have been de-
veloped for the detection of protein loss into the gas-
trointestinal tract. The diagnosis has been established 
by plasma alpha 1-antitrypsin (alpha 1-AT) clearance 
or nuclear studies. Alpha 1-AT is a serum enzyme 
with same molecular weight as albumin, and is resis-
tant to proteolysis by intestinal enzymes and not de-
graded in the intestine. The alpha 1-AT clearance test
is a reliable and less expensive method for evaluating 
gastrointestinal protein loss. However, this test often 
provides false negative results in case of protein leak-
age into the stomach, because alpha 1-AT is dena-
tured in the acidic gastric lumen (29, 39). In this occa-
sion, administration of acid suppressants such as 
histamine H2 receptor antagonist (H2RA) or proton 
pump inhibitor (PPI) may help to establish the correct 
alpha 1-AT clearance (33, 40, 41). 
 Nuclear studies are simple and useful methods to 
demonstrate the gastrointestinal protein loss. These in-
volved the use of intravenous administration of 
radiolabeled macromolecules such as 1251-labeled serum 
albumin, 51CrCL3, 51Cr-labeled albumin, and '''indium 
chloride (In-CI). Among several radioactive isotopes, 
we employed scanning with 111In-Cl, which combines 
with serum transferrin when administered intrave-
nously or in vitro (42-44). As leakage of plasma pro-
tein occurs, 11'1n-Cl leaks with transferrin into the gas-
trointestinal tract. This technique can clearly 
demonstrate gastrointestinal protein loss without col-
lecting feces (Fig. 6). Although nuclear studies have 
some disadvantages such as high cost and need for ra-
dioactive materials, they are simple and reliable tests 
for diagnosis of PLG.
Treatment of protein-losing gastropathy associated 
with H. pylori infection
Figure 6. Abdominal scintigraphic scan showing radioactiv-
ity in the duodenum (a; 5 hrs. after intravenous administra-
tion of "indium chloride) and colon (b; 24 hrs after admini-
stration), indicating gastrointestinal protein loss.
 The treatment of PLG should focus principally on 
the treatment of the underlying disease after it has 
been identified. Therapeutic choices, therefore, must 
involve clinical acumen, empiricism, and understand-
ing of the pathophysiology of the underlying disease 
process of each individual patient. The etiology of 
Menetrier's disease is not fully understood. Various 
etiologic factors were proposed including increased 
epidermal growth factors (EGF) in saliva (45. 46), 
immunological abnormalities including antibodies to 
gastric parietal cells (47), and finally infection with 
CMV in children (12) and H. pylori in adults (14-16). A 
retrospective analysis found that the disease was asso-
ciated with H. pylori in more than 90% of patients (16). 
It is reasonable, therefore, that primary therapy 
should be oriented for H. pylori infection. A plenty 
number of recent reports indicated that eradication of 
H. pylori with antibiotics and anti-ulcer drugs success-
fully improved PLG, being associated with resolution 
of gastric lesions such as Menetrier's disease and 
varioliform gastritis (15, 16, 33). This evidence 
strongly supports that H. pylori is an important etio-
logic factor for PLG.
  Before era of H. pylori, various treatments were tried 
for PLG including H2RA, PPI and octreotide, a long-
acting somatostatin analogue (46). However, only a 
few reports documented that H2RAs, cimetidine and 
ranitidine, were effective in the treatment of PLG. 
Kristensen and Nilsson (48) suggested that the 
cimetidine might decrease abnormal mucus secretion 
in a 37-year-old patient with Menetrier's disease, lead-
ing to resolution of PLG. Krag et al. (49) reported a 
case with Menetrier's disease that was successfully 
treated by cimetidine, and suggested based on EM 
findings that cimetidine decreases a paracellular pro-
tein secretion by 'tightening' the tight junctions of the 
gastric epithelium. However, the precise mechanism 
by which H2Rs improve protein loss remains unclear. 
 PPI also has been tried in the treatment of PLG. We 
reported a case with varioliform gastritis accompany-
ing PLG who was successfully treated by omeprazole 
alone (29). Ladas et al. (50) reported that excellent 
clinical remission of Menetrier's disease and the associ-
ated PLG was obtained with long-term omeprazole 
maintenance treatment. The mechanism for resolution 
of these conditions by PPI is unclear, but the follow-
ing mechanisms are suggested; (1) PPI improves ulcers 
and erosions where plasma protein leaks, (2) it may 
reduces mucus secretion from gastric mucosa, and (3) 
it may induce H. pylori suppression. Nevertheless, effi-
cacy of H2RA and PPI in the treatment of PLG is un-
stable and not established because there are a signifi-
cant number of reports denying their usefulness in 
single use (51, 52). Most of recent reports indicated 
that eradication therapy of H. pylori with antibiotics 
and PPI or H2RA is beneficial in the treatment of H. 
pylori-associated PLG (15-19, 50, 51). As stated previ-
ously, administration of H2RA or PPI alone may in-
duce clinical remission of PLG, although in rare occa-
sion. The reason for the difference in response to 
various treatments is unknown, but probably the se-
verity of the immune response against H. pylori is dif-
ferent in each case. 
 H. pylori is recognized to be a serious pathogen, but 
there is still controversy as to who should be treated. 
As in the guidelines, the eradication of H. pylori is 
strongly recommended in all patients with peptic 
ulcer and in those with low-grade gastric mucosa-
associated lymphoid tissue lymphoma. It may be also 
recommended in patients following gastric cancer re-
section. Although relationship between non-ulcer dys-
pepsia and H. pylori infection is still controversial, it 
may be worth to try the eradication therapy in in-
fected patients with functional dyspepsia, as it leads 
to long-term symptom improvement in a subset of pa-
tients (53). Lymphocytic gastritis and giant-fold
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gastropathy (Menetrier's disease) may also respond 
well to treatment (54). Therefore, treatment of H py-
lori infection in these patients with PLG is recom-
mended before other, more invasive treatment modali-
ties including surgical resection.
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